EGFR and non-small cell lung carcinoma: Understanding the genomic profile signature (GPS) following progression on EGFR-TKI therapy facilitates the exploration of targeted regimens to improve survival and quality of life in advanced NSCLC patients.10,11 Osimertinib overcomes the challenges posed by the EGFR T790M mutation, which often arises in patients treated with first- or second-generation EGFR-TKIs.10,11 Compared with first-generation EGFR-TKIs, osimertinib significantly improves PFS and OS for patients with EGFR-mutant NSCLC in the first-line treatment setting.1,2